Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 45,944

Document Document Title
WO/2018/219982A1
The present invention relates to pharmaceutical compositions comprising (E)-4-(2- (aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having chemical structure (I) or a pharmaceutically acceptable salt thereof as active pharmaceutical ...  
WO/2018/220034A1
The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA expression is beneficial for a range of medical disorders, such...  
WO/2018/218961A1
A use of ligustrazine nitrone derivatives and a pharmaceutical composition thereof in the preparation of medicine for preventing and treating diabetic complication diseases. The ligustrazine nitrone derivatives can be prepared into vario...  
WO/2018/221713A1
The purpose of the present invention is to solubilize a sparingly-soluble component in a solution, to provide a sparingly-soluble component-containing solution, to increase the solubility of a sparingly-soluble component in water (for ex...  
WO/2018/220490A1
Methods and compositions for treating ophthalmic disease, in particular retinal degeneration, including modulating Müller glia, restoring retinal synaptic connectivity and forming α2δ1-containing synapses, using postpartum-derived cel...  
WO/2018/221521A1
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives o...  
WO/2018/221543A1
The present invention provides: an I-type crystal of (E)-2-(7-trifluoromethyl chromane-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaph thalene-1-yl)acetamide having an excellent TRPV1 antagonistic activity; a medication and a medicat...  
WO/2018/221679A1
This 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative or a salt thereof has BRD4 inhibitory activity and is therefore useful as a drug, especially as an agent to prevent and/or treat diseases involving BRD4.  
WO/2018/220489A2
The invention provides for methods of obtaining cells from mammalian, preferably human, postpartum umbilical cord arterial tissue and use of these cells to treat ocular degenerative conditions. In particular, methods of the invention res...  
WO/2018/214958A1
Disclosed are a crystal form of an indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor and a preparation method therefor.  
WO/2018/215414A1
The present invention relates to the use of neurotrophins in the treatment of hearing disorders related to hearing loss using the transtympanic route of administration, in particular in the treatment of sudden deafness, blast-induced hea...  
WO/2018/215897A1
The present invention relates to a liquid mixture or solid mixture, in powder or granules, comprising or, alternatively, consisting of alginic acid and hyaluronic acid, or a salt thereof, for use in the treatment, in particular in the cu...  
WO/2018/214736A1
Provided are a polyhydroxyphthalazinone compound, a preparation method therefor and the use thereof, wherein the general formula of the chemical structure of the polyhydroxyphthalazinone compound is as shown by formula (I). The polyhydro...  
WO/2018/212152A1
[Problem] To provide an ophthalmic composition that is efficacious for preventing or treating myopia or ophthalmic diseases. In particular, to provide: an ophthalmic composition that is efficacious for growing children and young adults, ...  
WO/2018/212708A1
The present embodiments generally relate to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in treating, inhibiting or preventing glaucoma in a subject. Dextran sulfate of the embodiments achieves a reduction and ...  
WO/2018/205961A1
Disclosed in the present invention is an eye drop for treating eye dryness. With a pH value of 5.0-7.0, the eye drop consists of the following components in percentage by weight: 0.05-0.1% of an active component 5-hydroxy-1-beta-D-furano...  
WO/2018/207791A1
Provided is an Arc expression promoter that has a high safety and can be continuously taken. The Arc expression promoter comprises chlorogenic acid or a salt thereof as an active ingredient.  
WO/2018/208625A1
The present disclosure provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present disclosure comprise administering to a subject in need thereof a therapeutic composition comprising a...  
WO/2018/205022A1
There is provided an ocular drug delivery formulation comprising a delivery carrier comprising a cellulosic polymer and an anionic polysaccharide and nanoparticles comprising an amphiphilic non-ionizable block copolymer and a cannabinoid...  
WO/2018/209051A1
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative...  
WO/2018/206656A1
A pharmaceutical composition comprising a semifluorinated alkane of formula (I): F(CF2)n(CH2)mH, wherein n is an integer from 4 to 6, and m is an integer from 5 to 8, for use in the treatment or prevention of a disease or condition relat...  
WO/2018/208369A1
Disclosed herein are therapeutic uses of polymer conjugates, including SNA-120 and SNA-125, comprising an active agent linked to a polymer, wherein the active agent comprises an indolocarbazole compound or derivative thereof. The disclos...  
WO/2018/204359A1
This invention features compositions, methods, and kits for treating conditions associated with pathological ocular neovascularization, reducing scarring in the eye, treating dry eye, treating macular degeneration, and treating keratitis...  
WO/2018/204236A1
The present invention provides crystalline hydrates of the oxalate and succinate salts of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-te trahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phen ol. The invention also pr...  
WO/2018/202694A1
The present invention refers to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions containing them and to a process for the preparation of said compounds: Formula (I), whe...  
WO/2018/201516A1
A compound and an application thereof for treatment of cataract. The structural formula of the compound is as shown in formula I. The compound of formula I, a prodrug thereof, or a pharmaceutically acceptable salt thereof, can be used to...  
WO/2018/202889A1
The present invention relates to an ultrasound contrast agent for use in treating a retina disorder by transiently disrupting the blood-retinal barrier (BRB) of a human, wherein the ultrasound contrast agent is administered just before a...  
WO/2018/204759A1
Methods of treating or slowing the growth of a lesion associated with geographic atrophy and methods of evaluating a drug (brimonidine) or agent for use in treating, reducing the progression of or slowing the growth of a lesion associate...  
WO/2018/204515A1
The present disclosure provides methods for administering formulations to the suprachoroidal space of the eye to achieve targeted drug delivery to a desired site of action within the eye. The methods include using a pushing formulation t...  
WO/2018/202783A1
The present invention relates to a sterile aqueous ophthalmic solution comprising N-(N-acetylcysteinyl-)chitosan with a content of free thiol groups of from 80 to 280 umol/g polymer, for use in the treatment of a non-infectious corneal d...  
WO/2018/204868A1
The present disclosure provides methods for the treatment of an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis). In particular, the present disclosure provides methods for ...  
WO/2018/204238A1
The invention provides a compound of formula 1 formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions compris...  
WO/2018/203424A1
The present invention provides an allergic conjunctivitis treatment eye drop which provides improvement of medication adherence by, for example, reducing the number of instillation times and enabling instillation to be performed while a ...  
WO/2018/202855A1
The present invention relates to functionalized saccharides anti-inflammatory agents which acts upon inflammatory mechanisms in mammals, in particular anti-inflammatory agents which act upon the expression of at least one cytokine by sup...  
WO/2018/204233A1
The invention relates to methods of treating ocular diseases and certain respiratory diseases using the compound 5-ethyl-2-fluoro~4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)ph enol...  
WO/2018/201007A2
Compounds, compositions, kits and methods for performing angiography related to ocular diseases, are disclosed.  
WO/2018/196861A1
The present invention relates to the field of pharmaceuticals, and in particular to a guanidine derivative containing a furan structure and a composition thereof. The derivative and the composition thereof can be used for preparing pharm...  
WO/2018/199287A1
The present disclosure provides: a composition for treating and/or preventing crystalline retinopathy, the composition containing a cholesterol accumulation inhibitor; a method for treating and/or preventing crystalline retinopathy, the ...  
WO/2018/199777A1
The present invention provides novels method of targeting delivery of a compound to hypoxic cells, for example treatment of diseases and disorders associated with hypoxia, comprising administration of a construct comprising a targeting c...  
WO/2018/200994A1
A device includes a frame, a rotatable housing and a permanent magnet. The frame is configured to be worn adjacent an eye region of a wearer. The rotatable housing is coupled to the frame. The permanent magnet is coupled to the rotatable...  
WO/2018/199291A1
The purpose of the present invention is to discover a novel compound having an excellent β-lactamase-inhibiting activity, and to provide a useful prophylactic or therapeutic agent for bacterial infectious diseases which comprises a comb...  
WO/2018/199180A1
The present invention provides an aqueous ophthalmic composition comprising two kinds of methylcelluloses, polyethylene glycol, polyvinyl pyrrolidone, and a citric acid or a pharmaceutically acceptable salt thereof. The composition of th...  
WO/2018/200980A1
Systems and methods for detecting single nucleotide polymorphisms (SNPs) associated with keratoconus (KC) in a sample from a subject are described.  
WO/2018/199224A1
The purpose of the present invention is to provide a novel anti-allergic agent. The present invention provides an anti-allergic agent containing a quinolone antimicrobial agent.  
WO/2018/194119A1
Provided is an ophthalmic composition from which sesame oil or castor oil can be released easily by the dilution with a tear fluid and therefore the sesame oil or castor oil can be supplied to a tear oil layer. An ophthalmic composition ...  
WO/2018/193408A1
Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reage...  
WO/2018/195411A1
The present invention provides methods, compositions, and kits for treating retinopathy, including diabetic retinopathy and macular degeneration, in a subject in need.  
WO/2018/193367A1
The present disclosure relates to novel pharmaceutical composition comprising Alcaftadine and Nepafenac along with antibacterial and/or antiviral and/or antifungal drug in the treatment of ophthalmic disorders which counteracts the aller...  
WO/2018/193120A1
The present invention provides a method and compositions for treating or preventing a cicatrising eye inflammatory disorder, in particular Sjögren's syndrome, mucous membrane pemphigoid or atopic keratoconjunctivitis. The method compris...  
WO/2018/191357A1
The present invention relates to a pre-filled syringe containing Moxifloxacin and comprising a plunger, a barrel, a needle with gauge, kits comprising this syringe and the use of the syringe for the administration of Moxifloxacin for pos...  

Matches 1 - 50 out of 45,944